Express Pharma

GE Healthcare’s FlexFactory to power DRL’s biosimilar expansion plans

257

FlexFactory will make DRL biopharmaceutical manufacturing set-up more flexible and efficient

GE Healthcare announced that Dr Reddy’s Laboratories (DRL) will install India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad. FlexFactory will make DRL biopharmaceutical manufacturing set-up more flexible and efficient, strengthening the company’s position in the global biosimilars market and allowing DRL to continue increasing patient access across the world for biotech-based therapies.

The new FlexFactory will help DRL increase its capacity to meet both the expected growth of its currently marketed biosimilars as well as support the launch of a significant portfolio of new biosimilar products in the years to come. With FlexFactory, DRL will be able to increase its manufacturing capacity swiftly as the overall project set-up timeline for FlexFactory is typically 9 to 12 months.

FlexFactory wil enable DRL transition from stainless steel to single-use technologies that bring enhanced flexibility and efficiency into their manufacturing set-up. Single-use technologies facilitate multi-product manufacturing and improve productivity by increasing the number of lots manufactured, as the change over time between products can be reduced by 50 per cent or more.

- Advertisement -

Comments are closed.